フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT...
Cortex Pharmaceuticals, Inc. (NYSE Amex (COR)) reported that it has received a delisting notification from the NYSE Amex LLC...
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-161143 PROSPECTUS CORTEX PHARMACEUTICALS, INC. 12,120,939 Shares of...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NOTICE OF EFFECTIVENESS Effective Date: August 20, 2009 Form:...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current...
Cortex Pharmaceuticals, Inc. (NYSE Amex: COR) reported a net loss applicable to common stock of $2,778,000, or $0.06 per share...
Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. FORM D OMB APPROVAL OMB Number: 3235-0076 Expires: September 30...
Table of Contents As Filed with the Securities and Exchange Commission on August 7, 2009 Registration No. ...
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to...
Cortex Pharmaceuticals, Inc. (NYSE Amex: COR) reported that it has entered into a definitive agreement with a single...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約